Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Organogenesis Holdings ( (ORGO) ).
On December 22, 2025, Organogenesis Inc. amended its leases for two key facilities at 65 Dan Road and 150 Dan Road in Canton, Massachusetts, extending the terms from their current expiration date of December 31, 2027 to December 31, 2032, with an additional two-year renewal option through December 31, 2034. The amendments lock in a rent structure tied to at least 103% of the 2027 annual rents, with potential adjustments to fair market value and 3% annual increases, formalizing long-term control over critical manufacturing, logistics, and R&D space. Because the properties are owned, directly or indirectly, by major shareholders and a sitting director, the transactions were reviewed as related-party dealings; the company’s Audit Committee concluded the lease amendments were fair, reasonable, and in the best interests of the company and its stockholders, potentially reducing governance risk around these arrangements.
The most recent analyst rating on (ORGO) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.
Spark’s Take on ORGO Stock
According to Spark, TipRanks’ AI Analyst, ORGO is a Neutral.
Organogenesis Holdings’ overall stock score reflects significant challenges in financial performance, particularly in profitability and cash flow management. Despite strong revenue growth and positive strategic developments noted in the earnings call, the negative P/E ratio and technical indicators suggest caution. The company’s ability to address these financial and operational challenges will be crucial for future performance.
To see Spark’s full report on ORGO stock, click here.
More about Organogenesis Holdings
Organogenesis Holdings Inc., through its wholly owned subsidiary Organogenesis Inc., operates from its Canton, Massachusetts headquarters, where key buildings are dedicated to manufacturing, shipping, operations, and research and development, supporting the company’s broader activities in its sector.
Average Trading Volume: 1,752,754
Technical Sentiment Signal: Buy
Current Market Cap: $669.5M
Learn more about ORGO stock on TipRanks’ Stock Analysis page.